Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your cal­en­dars for Oc­to­ber 28 at 4:20 pm EDT.

That’s when Mi­rati $MRTX will un­veil its first peek at the ear­ly clin­i­cal da­ta avail­able on MRTX849 in pre­sen­ta­tions at the AACR-NCI-EORTC In­ter­na­tion­al Con­fer­ence on Mol­e­c­u­lar Tar­gets and Can­cer Ther­a­peu­tics in Boston.

Mi­rati has been ex­pe­ri­enc­ing the full ef­fect of a ri­val’s ini­tial suc­cess at tar­get­ing the G12C pock­et found on KRAS, of­fer­ing the biotech some sup­port on the con­cept they’re af­ter — and biotech fans a race to the top. Am­gen made a big splash with its first pos­i­tive snap­shot on lung can­cer, but de­flat­ed sky-high ex­pec­ta­tions as it proved hard­er to find sim­i­lar ben­e­fits in oth­er types of can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER